These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Advances in the Study of Antitumour Immunotherapy for Newcastle Disease Virus. Meng Q; He J; Zhong L; Zhao Y Int J Med Sci; 2021; 18(11):2294-2302. PubMed ID: 33967605 [TBL] [Abstract][Full Text] [Related]
3. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy. Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476 [TBL] [Abstract][Full Text] [Related]
4. Targeted cancer immunotherapy with genetically engineered oncolytic Salmonella typhimurium. Guo Y; Chen Y; Liu X; Min JJ; Tan W; Zheng JH Cancer Lett; 2020 Jan; 469():102-110. PubMed ID: 31666180 [TBL] [Abstract][Full Text] [Related]
5. Intratumoral Immunotherapy: From Trial Design to Clinical Practice. Champiat S; Tselikas L; Farhane S; Raoult T; Texier M; Lanoy E; Massard C; Robert C; Ammari S; De Baère T; Marabelle A Clin Cancer Res; 2021 Feb; 27(3):665-679. PubMed ID: 32943460 [TBL] [Abstract][Full Text] [Related]
10. Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC. Humbert M; Guery L; Brighouse D; Lemeille S; Hugues S Cancer Res; 2018 Jun; 78(12):3280-3292. PubMed ID: 29588348 [TBL] [Abstract][Full Text] [Related]
11. Interleukin-6-mediated resistance to immunotherapy is linked to impaired myeloid cell function. Beyranvand Nejad E; Labrie C; van der Sluis TC; van Duikeren S; Franken KLMC; Roosenhoff R; Arens R; van Hall T; van der Burg SH Int J Cancer; 2021 Jan; 148(1):211-225. PubMed ID: 32875568 [TBL] [Abstract][Full Text] [Related]
12. Non-replicating Newcastle Disease Virus as an adjuvant for DNA vaccine enhances antitumor efficacy through the induction of TRAIL and granzyme B expression. Mohebbi A; Ebrahimzadeh MS; Baghban Rahimi S; Saeidi M; Tabarraei A; Mohebbi SR; Shirian S; Gorji A; Ghaemi A Virus Res; 2019 Feb; 261():72-80. PubMed ID: 30599161 [TBL] [Abstract][Full Text] [Related]
13. Antiviral Responses in Cancer: Boosting Antitumor Immunity Through Activation of Interferon Pathway in the Tumor Microenvironment. Vitiello GAF; Ferreira WAS; Cordeiro de Lima VC; Medina TDS Front Immunol; 2021; 12():782852. PubMed ID: 34925363 [TBL] [Abstract][Full Text] [Related]
15. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine. Smalley Rumfield C; Pellom ST; Morillon Ii YM; Schlom J; Jochems C J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554612 [TBL] [Abstract][Full Text] [Related]
16. Intratumoral immunotherapy: using the tumor as the remedy. Marabelle A; Tselikas L; de Baere T; Houot R Ann Oncol; 2017 Dec; 28(suppl_12):xii33-xii43. PubMed ID: 29253115 [TBL] [Abstract][Full Text] [Related]
17. Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity. Wang G; Chow RD; Bai Z; Zhu L; Errami Y; Dai X; Dong MB; Ye L; Zhang X; Renauer PA; Park JJ; Shen L; Ye H; Fuchs CS; Chen S Nat Immunol; 2019 Nov; 20(11):1494-1505. PubMed ID: 31611701 [TBL] [Abstract][Full Text] [Related]
18. Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas. Enríquez Pérez J; Kopecky J; Visse E; Darabi A; Siesjö P BMC Cancer; 2020 Jan; 20(1):7. PubMed ID: 31900109 [TBL] [Abstract][Full Text] [Related]